Skip to content
Saturday 8 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

Indivior

  • Indivior share price dives on US court defeat which could hit sales hard

    February 5, 2019

    Pharmaceutical company Indivior’s share price crashed 17 per cent this morning after a US court ruling opened the way for rivals to sell a generic version of its opioid addiction treatment drug in the US. Shares fell from 113p last night to 93p this morning following the decision. The US Court of Appeals for the Federal [...]

  • Indivior sells China opioid treatment drug as it looks to focus on its core products

    February 4, 2019

    Drug company Indivior has agreed to sell its rights related to the Sai Bo Song (buprenorphine, naloxone) tablet in China to Zhejiang Pukang Biotechnology for $122.5m (£93.6m). The pharmaceutical company said the sale of the tablet was part of its strategy to focus its resources on its core assets and markets. "The divestiture of the [...]

  • Indivior rallies as it plays rivals at their own game

    December 18, 2018

    Indivior shares jumped over 17 per cent today as the company decided to take on generic copies of its star drug Suboxone by launching a cheaper version. The opioid treatment is facing challenges in the US where it is locked in a court battle with Dr Reddy’s Laboratories (DRL). Last week Indivior won a case [...]

  • Indivior shares crash as US Court of Appeal overturns drug ruling

    November 21, 2018

    FTSE 250 pharma giant Indivior saw its share price plunge more than 10 per cent in early morning trading, after a court ruling against the drug maker last night rocked investor confidence. The US Court of Appeal yesterday decided that a generic drug company, Dr Reddy’s Laboraties, would be allowed to sell a copycat version [...]

  • Indivior shares plunge as firm reduces full-year sales guidance

    September 27, 2018

      Shares in addiction treatment pharma firm Indivior took a eight per cent hit this morning after it said sales for the year would be lower than expected.  Indivior on Wednesday said full-year sales would be revised down to between $990m (£755m) and $1.02bn (£780m) from its February estimate of between $1.13bn and $1.17bn.  In particular, it [...]

  • Indivior share price hit as US rivals hurt profits

    February 11, 2015

    Shares at Indivior crumbled during yesterday’s trade but recovered to be down only 2.4 per cent. The FTSE-listed company which specialises in the production of Suboxone, a substitute used by recovering heroin addicts, was spun off last December from Reckitt Benckiser – the Slough-based health giant whose brands range from Dettol to Durex. The company [...]

Posts pagination

  • Previous
  • Page 1
  • Page 2

Trending Articles

  • WPP slashes jobs as revenue continues to fall

  • Liverpool owners tipped to sell – but not to Amazon boss Bezos – by former CEO

  • Revolut founder’s wealth set to balloon amid talks of share award at $500bn valuation

  • Starling plans to ‘come out swinging’ in diversification bid

  • As it happened: Stocks rise despite new tensions in Strait of Hormuz; Oil price climbs

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook